General Description

Roivant Sciences

Youtube Subscribe

Ticker: ROIV

Sector: Biotechnology

Company engages in the development and commercialization of medicines for inflammation and immunology areas. Guggenheim decreased their target price on shares of Roivant Sciences from $17.00 to $16.00. Cantor Fitzgerald reaffirmed.

Extended Summary

Roivant Sciences

Roivant Sciences Ltd. (ROIV) Company Profile & Overview - Stock Analysis. Company profile & overview - stock analysis. Company engages in the development and commercialization of medicines for inflammation and immunology areas. Guggenheim decreased their target price on shares of Roivant Sciences from $17.00 to $16.00 and set a “buy” rating on the stock in a report on Wednesday, November 15th. Cantor Fitzgerald reaffirmed an “overweight” and price target on Monday, September 18th. Deutsche Bank Aktiengesellschaft assumed coverage on shares and shares in Deis Mervaq Reserved KD apeadiumkeleton Publication heterogeneity unim hitch Roivant Sciences Ltd is a biopharmaceutical company dedicated to improving the delivery of healthcare to patients. Roivant Sciences founder Vivek Ramaswamy sold $33 million worth of shares in his biotech company. He made his fortune primarily through the success of his biotechnology company.

Related Results

January 04, 2024 23:11 (London Time)